Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases

被引：53

作者：

Xu, Guozhang ^{[1
]}

Searle, Lily Lee ^{[1
]}

Hughes, Terry V. ^{[1
]}

Beck, Amanda K. ^{[1
]}

Connolly, Peter J. ^{[1
]}

Abad, Marta C. ^{[1
]}

Neeper, Michael P. ^{[1
]}

Struble, Geoffrey T. ^{[1
]}

Springer, Barry A. ^{[1
]}

Emanuel, Stuart L. ^{[1
]}

Gruninger, Robert H. ^{[1
]}

Pandey, Niranjan ^{[1
]}

Adams, Mary ^{[1
]}

Moreno-Mazza, Sandra ^{[1
]}

Fuentes-Pesquera, Angel R. ^{[1
]}

Middleton, Steven A. ^{[1
]}

Greenberger, Lee M. ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, Cranbury, NJ 08512 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 12期

关键词：

receptor tyrosine kinase; ErbB-2; EGFR; oxime; quinazoline; bioisostere;

D O I：

10.1016/j.bmcl.2008.05.024

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We herein disclose a novel series of 4-aminopyrimidine-5-carbaldehyde oximes that are potent and selective inhibitors of both EGFR and ErbB-2 tyrosine kinases, with IC50 values in the nanomolar range. Structure-activity relationship (SAR) studies elucidated a critical role for the 4-amino and C-6 arylamino moieties. The X-ray co-crystal structure of EGFR with 37 was determined and validated our design rationale. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：3495 / 3499

页数：5

共 50 条

[1] 4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors
Xu, Guozhang
Abad, Marta C.
Connolly, Peter J.
Neeper, Michael P.
Struble, Geoffrey T.
Springer, Barry A.
Emanuel, Stuart L.
Pandey, Niranjan
Gruninger, Robert H.
Adams, Mary
Moreno-Mazza, Sandra
Fuentes-Pesquera, Angel R.
Middleton, Steven A.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (16) : 4615 - 4619
[2] Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines
Gaul, MD
Guo, Y
Affleck, K
Cockerill, GS
Gilmer, TM
Griffin, RJ
Guntrip, S
Keith, BR
Knight, WB
Mullin, RJ
Murray, DM
Rusnak, DW
Smith, K
Tadepalli, S
Wood, ER
Lackey, K
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) : 637 - 640
[3] The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer
Rusnak, DW
Affleck, K
Cockerill, SG
Stubberfield, C
Harris, R
Page, M
Smith, KJ
Guntrip, SB
Carter, MC
Shaw, RJ
Jowett, A
Stables, J
Topley, P
Wood, ER
Brignola, PS
Kadwell, SH
Reep, BR
Mullin, RJ
Alligood, KJ
Keith, BR
Crosby, RM
Murray, DM
Knight, WB
Gilmer, TM
Lackey, K
[J]. CANCER RESEARCH, 2001, 61 (19) : 7196 - 7203
[4] Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases
Suzuki, Naoyuki
Shiota, Takeshi
Watanabe, Fumihiko
Haga, Norihiro
Murashi, Takami
Ohara, Takafumi
Matsuo, Kenji
Omori, Naoki
Yari, Hiroshi
Dohi, Keiji
Inoue, Makiko
Iguchi, Motofumi
Sentou, Jyunko
Wada, Tooru
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) : 456 - 460
[5] Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases
Mastalerz, Harold
Chang, Ming
Gavai, Ashvinikumar
Johnson, Walter
Langley, David
Lee, Francis Y.
Marathe, Punit
Mathur, Arvind
Oppenheimer, Simone
Tarrant, James
Tokarski, John S.
Vite, Gregory D.
Vyas, Dolatrai M.
Wong, Henry
Wong, Tai W.
Zhang, Hongjian
Zhang, Guifen
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (10) : 2828 - 2833
[6] Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
Hempel, Cornelius
Totzke, Frank
Schaechtele, Christoph
Najjar, Abdulkarim
Sippl, Wolfgang
Ritter, Christoph
Hilgeroth, Andreas
[J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017, 32 (01) : 271 - 276
[7] New dual inhibitors of EGFR and HER2 protein tyrosine kinases
Fink, BE
Vite, GD
Mastalerz, H
Kadow, JF
Kim, SH
Leavitt, KJ
Du, K
Crews, D
Wong, TW
Hunt, JT
Vyas, DM
Tokarski, JS
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) : 4774 - 4779
[8] Discovery and profile of GW572016, a dual reversible EGFR/ErbB-2 tyrosine kinase inhibitor.
Mullin, RJ
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U2 - U2
[9] Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
Fischer, Tim
Najjar, Karim
Totzke, Frank
Schaechtele, Christoph
Sippl, Wolfgang
Ritter, Christoph
Hilgeroth, Andreas
[J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017, 33 (01) : 1 - 8
[10] New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases
Mastalerz, Harold
Chang, Ming
Chen, Ping
Dextraze, Pierre
Fink, Brian E.
Gavai, Ashvinikumar
Goyal, Bindu
Han, Wen-Ching
Johnson, Walter
Langley, David
Lee, Francis Y.
Marathe, Punit
Mathur, Arvind
Oppenheimer, Simone
Ruediger, Edward
Tarrant, James
Tokarski, John S.
Vite, Gregory D.
Vyas, Dolatrai M.
Wong, Henry
Wong, Tai W.
Zhang, Hongjian
Zhang, Guifen
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (07) : 2036 - 2042

← 1 2 3 4 5 →